Search results
Results from the WOW.Com Content Network
The most common side effects reported with naltrexone are gastrointestinal complaints such as diarrhea and abdominal cramping. [3] These adverse effects are analogous to the symptoms of opioid withdrawal, as the μ-opioid receptor blockade will increase gastrointestinal motility. The side effects of naltrexone by incidence are as follows: [3]
Common (≥1/100 to <1/10) side effects include candidiasis, headache, tremor, palpitations, throat irritation, coughing, and dysphonia. [7] Pneumonia is a common side effect in people with COPD, and other, less common side effects have been documented.
Common side effects with the pills include feeling tired, vomiting, and joint pains. [16] Serious side effects include an increased risk of infection, loss of bone strength, and cataracts. [16] Long-term use of the pill form may cause adrenal insufficiency. [16] Stopping the pills suddenly following long-term use may therefore be dangerous. [16]
Different sources note different incidence of side effects. The most common side effect is breakthrough bleeding. Combined oral contraceptive pills can improve conditions such as dysmenorrhea, premenstrual syndrome, and acne, [105] reduce symptoms of endometriosis and polycystic ovary syndrome, and decrease the risk of anemia. [106]
Vonoprazan, sold under the brand name Voquezna among others, is a first-in-class potassium-competitive acid blocker medication. [2] [1] Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.
Although a phase II trial for an injectable male contraceptive was halted in 2011 by an independent data safety monitoring board due likely to rare adverse effects experienced by some participants, [197] [67] leading many popular articles to suggest men could not tolerate side effects similar to those that many women endure on hormonal birth ...
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...
Oliceridine is a μ-opioid receptor biased agonist developed by Trevena.In cell-based (in vitro) research, oliceridine elicits robust G protein signaling, with potency and efficacy similar to that of morphine, but with less β-arrestin 2 recruitment and receptor internalization. [5]